NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Marker Therapeutics, Inc. (MRKR) Stock Analysis

Marker Therapeutics, Inc. (MRKR) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

MRKR

$1.18

−$0.06 (−4.84%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MRKR with… →

MRKR Key Statistics

As of Sep 4, 2026
Trading
Open
$1.25
Previous Close
$1.24
Day's Range
1.18–1.31
52-Week Range
0.83–2.46
Volume
35.30K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.53
Valuation
Market Cap
$19.67M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
5.55
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.36
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$12.16M
Profit marginThe share of revenue left as profit after all costs and taxes.
−245.51%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
16.67M
1-Year Return
+37.21%
Dividend and dates
Avg Volume
65.55K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MRKR Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−20.81%
2025−52.09%
2024−43.45%
2023+103.70%
2022−71.58%
2021−34.48%
2020−49.65%
2019−48.11%
2018+41.58%
2017+1.03%
2016 (partial year)−41.21%

As of September 4, 2026.

MRKR Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$12.16M—
2024$0.00−$10.73M—
2023$3.31M−$8.24M−248.8%
2022$0.00−$29.93M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$12.44M−$12.16M—
2024$0.00—−$11.12M−$10.73M—
2023$3.31M—−$11.27M−$8.24M−248.8%
2022$0.00—−$19.79M−$29.93M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MRKR Valuation vs Biotechnology Median

Median of 656 stocks
MetricMRKRBiotechnology medianvs median
P/S ratio5.5515.2664% below
Profit margin−245.51%0.00%245.5 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Marker Therapeutics, Inc. (MRKR) is capitalised at $19.67M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 5.

The most recent close on file for MRKR is $1.18, dated September 4, 2026. That is −$0.06 (−4.84%) against the previous close. The 52-week range on file runs from $0.83 to $2.46. The latest close sits 42.17% above that 52-week low.

Financial Health

In fiscal 2025, Marker Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $12.16M. Profit margin runs at −245.51%. That is 245.5 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −0.36.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 5.55 times revenue. On price-to-sales that is 63.66% below the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +37.21%. Across 10 years the annualized return works out at −32.35%. The reported beta is 1.53. Daily returns over the trailing 10 years annualize to a volatility of 100.05%.

Growth & Income

The record shows no dividend for MRKR.

So far in 2026 the price is −20.81%. The strongest complete calendar year on file is 2023 at +103.70%; the weakest is 2022 at −71.58%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

Marker Therapeutics, Inc. (MRKR) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Marker Therapeutics, Inc. MRKR $19.67M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Marker Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Marker Therapeutics, Inc.

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.

Visit website →